Stuart Varney and Taylor Riggs discuss Eli Lilly’s massive revenue surge driven by GLP-1 obesity drugs Mounjaro and Zepbound, and how the diet craze is negatively impacting food brands like Kraft Heinz.
Eli Lilly stock surges over 7% as soaring demand for GLP-1 weight loss drugs Mounjaro and Zepbound drives massive revenue growth. Stuart Varney and Taylor Riggs analyze the pharmaceutical boom and its surprising ripple effects across the food industry. Riggs notes that processed food giant Kraft Heinz is already experiencing lower sales volume as the obesity drug craze expands.
Read the full article here